Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
April 15 2022 - 4:05PM
Business Wire
Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage
biotechnology company discovering and developing breakthrough
treatments for immune-mediated and oncologic disorders, today
announced that the company’s Board of Directors has granted one
employee a nonqualified stock option to purchase 100,000 shares of
its common stock with an exercise price of $15.44 per share, which
is equal to the closing price of Kezar’s common stock on April 13,
2022, the grant date of the award. This grant was part of an
inducement award material to the individual’s employment with
Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option will vest over a four-year period, with 25% of
the option vesting on the first anniversary of the employee’s date
of hire, and 1/48th of the option vesting monthly thereafter,
subject to the employee’s continued employment with Kezar on such
vesting dates. The option is subject to the terms and conditions of
Kezar’s 2022 Inducement Plan and the stock option agreement
covering the grant.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical
company discovering and developing breakthrough treatments for
immune-mediated and oncologic disorders. The company is pioneering
first-in-class, small-molecule therapies that harness master
regulators of cellular function to inhibit multiple drivers of
disease via single, powerful targets. Zetomipzomib, its lead
development asset, is a selective immunoproteasome inhibitor being
evaluated in Phase 2 clinical trials in lupus nephritis,
dermatomyositis and polymyositis. KZR-261 is the first anti-cancer
clinical candidate from the company’s platform targeting the Sec61
translocon and the protein secretion pathway. An open-label
dose-escalation Phase 1 clinical trial of KZR-261 to assess safety,
tolerability and preliminary tumor activity in solid tumors is
underway. For more information, visit
www.kezarlifesciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220415005028/en/
Gitanjali Jain Vice President, Investor Relations and External
Affairs 650-269-7523 gjain@kezarbio.com
Liza Sullivan Argot Partners 212-600-1902
kezar@argotpartners.com
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Apr 2023 to Apr 2024